• Publications
  • Influence
China offers alternative gateway for experimental drugs
Several experimental biologic drugs that failed in the US and Europe have been recently approved in China.
First US approval for a transgenic animal drug
  • J. Kling
  • Biology, Medicine
  • Nature Biotechnology
  • 1 April 2009
TLDR
The animal biotech sector reached a landmark in February when the US Food and Drug Administration announced the approval of ATryn, an anticoagulant protein derived from the milk of transgenic goats, the first animal drug to be approved in the US. Expand
Ultrafast DNA sequencing
  • J. Kling
  • Biology, Medicine
  • Nature Biotechnology
  • 1 December 2003
Single-molecule sequencing may be the wave of the future, but don't count out microfluidics yet. Jim Kling reports.
Merck moves into biotech
  • J. Kling
  • Business, Medicine
  • Nature Biotechnology
  • 6 July 2006
In May, Merck, one of the oldest and stodgiest pharmaceutical companies, entered the biotech arena by announcing its plans to purchase two protein manufacturing firms: GlycoFi for $400 million andExpand
Safety signal dampens reception for mipomersen antisense
  • J. Kling
  • Medicine
  • Nature Biotechnology
  • 1 April 2010
TLDR
The latest trial results provide validation that antisense drugs do have sufficient potency to rival traditional small-molecule drugs, and Alan Gewirtz says this is a “shot in the arm” for the field. Expand
The search for a sequencing thoroughbred
  • J. Kling
  • Medicine, Biology
  • Nature Biotechnology
  • 1 November 2005
Just three months after the results of two innovative and potentially cost-effective sequencing technologies were announced, one instrument has been launched on the market. Does this mean the $1,000Expand
Hypoxia-activated prodrugs forge ahead in cancer
  • J. Kling
  • Medicine, Biology
  • Nature Biotechnology
  • 7 May 2012
TLDR
Of companies developing hypoxia-activated drugs, two have dropped their candidates, including Paris-based Sanofi, which abandoned the drug tirapazamine in 2007 due to poor efficacy in head and neck cancer, and Novacea, whose small-molecule prodrug, banoxantrone, foundered in 2008. Expand
A GIS Assessment of Alpine Biodiversity at a Range of Scales
Biodiversity is a complex concept that covers diversity in a continuum of organisational levels from genetic diversity within populations to functional diversity at a global scale. The scale problemExpand
Labeling for better or worse
  • J. Kling
  • Biology, Medicine
  • Nature Biotechnology
  • 9 December 2014
As US legislatures and voters continue to wrestle with GM labeling, what is at stake? Jim Kling investigates.
Protecting medicine's wild pharmacy
  • J. Kling
  • Biology, Medicine
  • Nature Plants
  • 4 May 2016
Medicinal plants, often harvested directly from the wild, are under increasing pressure from climate change, development and over-exploitation in response to increasing demand. Is cultivation theExpand
...
1
2
3
4
5
...